Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL27508163 | 0.88 | L3MBTL1 (0.49) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL1950950 | 0.79 | L3MBTL1 (0.52) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL6680308 | 0.78 | GAA (0.49) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL29955418 | 0.76 | HSD17B10 (0.43) | L3MBTL1HSD17B10HPGDTP53MAPK1 | |
| SCHEMBL10973292 | 0.76 | L3MBTL1 (0.58) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL11084732 | 0.76 | L3MBTL1 (0.58) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL9592410 | 0.74 | L3MBTL1 (1.00) | L3MBTL1HPGDGAATP53MAPK1 | |
| SCHEMBL5738824 | 0.74 | GAA (0.56) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL8194267 | 0.74 | GAA (0.49) | L3MBTL1HSD17B10HPGDGAATP53 | |
| SCHEMBL4311403 | 0.74 | GAA (0.49) | L3MBTL1HSD17B10HPGDGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1242004-A | Process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives | PROCTER & GAMBLE (US) | 2000-01-19 | — | — | CN | claimed |
| EP-3660011-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2020-06-03 | — | — | EP | disclosed |
| WO-2018166528-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| CN-108137638-A | Bridging type nucleic acid GuNA, its manufacturing method and midbody compound | 田边三菱制药株式会社 | 2018-06-08 | — | — | CN | disclosed |
| CN-105143209-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2018-03-13 | — | — | CN | disclosed |
| US-9732109-B2 | Pesticidal compositions | DOW AGROSCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9663497-B2 | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-30 | — | — | US | disclosed |
| US-20160340337-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | NOVASSAY S.A. (CH) | 2016-11-24 | — | — | US | disclosed |
| EP-2247603-B1 | PESTICIDAL COMPOSITIONS | DOW AGROSCIENCES LLC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9434715-B2 | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| WO-1999001452-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1999001131-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
| EP-0889726-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5756499-A | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997025045-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-4941910-A | 4-halo-2-oxy or sulfonyl-4-amino substituted pyrimidines as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-17 | — | — | US | disclosed |
| US-4711959-A | REACTING 2-ALKYLSULPHONYL-PYRIMIDINE WITH CYANAMIDE OR METAL SALT OF CYANAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1987-12-08 | — | — | US | disclosed |
| US-4352928-A | ANTIINFLAMMATORY, HYPOGLYCEMIC, ANTICOAGULANT, ANOREXIGENIC, SEROTONIN EFFEC | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1982-10-05 | — | — | US | disclosed |
| EP-0022481-A1 | 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions | Mitsubishi Yuka Pharmaceutical Co., Ltd. (JP) | 1981-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340337-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | L3MBTL1 4114/4885HSD17B10 4802/4885HPGD 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.